论文部分内容阅读
目的采用临床随机对照研究维生素D3添加治疗复发型多发性硬化(MS)患者的临床疗效和安全性。方法缓解复发型MS患者72例,随机分成维生素D3组(甲泼尼龙+维生素D3治疗)和激素组(甲泼尼龙治疗,为对照),每组36例,维生素D3组在激素治疗基础上添加骨化三醇胶丸口服。治疗前后记录症状、体征,评定扩展残疾状态评分(EDSS)分值,治疗后随访2年。疗效评定考核指标采用MS年复发次数,复发间隔时间,EDSS评分下降值。结果治疗前维生素D3组年龄、病程、复发次数、EDSS数值与激素组比较,差异无统计学意义(P>0.05);治疗后第6、12个月EDSS数值与激素组比较,差异也无统计学意义(P>0.05)。治疗后第24个月,维生素D3组与激素组比较EDSS数值(P<0.05)、年复发次数(P<0.05)、复发间隔时间(P<0.01),差异有统计学意义。结论维生素D3添加治疗能减少MS的复发次数、延长复发间歇时间、延缓残疾进展速度。
Objective To investigate the clinical efficacy and safety of vitamin D3 supplementation in patients with recurrent multiple sclerosis (MS) by randomized controlled clinical trial. Methods 72 patients with relapsed MS were randomly divided into vitamin D3 group (methylprednisolone + vitamin D3 treatment) and hormone group (methylprednisolone treatment as control), 36 patients in each group. Vitamin D3 group was added on the basis of hormone therapy Calcitriol capsules oral. The symptoms and signs were recorded before and after treatment, and EDSS scores were scored. The patients were followed up for 2 years after treatment. Efficacy evaluation indicators using MS annual recurrences, recurrence interval, EDSS score decreased. Results Before treatment, there was no significant difference in the age, course of disease, number of relapse and EDSS between hormone group and vitamin D3 group (P> 0.05). There was no statistical difference in EDSS between 6 and 12 months after treatment Significance (P> 0.05). At 24 months after treatment, the EDSS value (P <0.05), the number of annual recurrences (P <0.05) and the recurrence interval (P <0.01) between the vitamin D3 group and the hormone group were significantly different. Conclusion Vitamin D3 treatment can reduce the number of MS relapse, prolong the recurrence interval and delay the progress of disability.